Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA: Omalizumab in Uncontrolled Perennial Moderate-to-Severe Allergic Rhinitis
ChiCTR2500109003Phase 4Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of omalizumab in allergic rhinitis (AR) (3 arms), sponsored by Yantai Yuhuangding Hospital. Primary endpoint: Total Nasal Symptom Scores (rTNSS) change from baseline at Week 16. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
omalizumab
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on ChiCTR2500109003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109003.